ZASOCITINIB
TAK-279-PsO-3003
Phase 3 small_molecule active
Quick answer
ZASOCITINIB for Moderate to Severe Plaque Psoriasis is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Moderate to Severe Plaque Psoriasis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active